Hüseyin AKILLI, Ali AYHAN, Samed RAHATLI, Ozden ALTUNDAG, Nadire KUCUKOZTAS, Arzu OGUZ, Zohrab ABDUYEV

Impact of comorbidities on recurrence rates and survival in patients with endometrial cancer

Aim: Endometrial cancer (EC) is mostly seen in elderly population, the impact of comorbid conditions on clinical outcomes andsurvival of EC is a topic of increasing interest. The aim of this study was to determine the association of diabetes mellitus (DM),hypertension (HT) and metformin use with survival in patients with EC.Material and Methods: Clinical and tumor characteristics of 410 patients who underwent surgery for EC in our institution between2006 and 2012 were reviewed. Demographic features, histological subtypes, stage, type of surgery, comorbidities, treatmentmodalities and patient outcomes in terms of relapse-free survival (RFS) and overall survival (OS) were assessed.Results: Median follow-up was 39 months. The presence of HT and DM were associated with overall survival after adjusted forage, disease stage and grade (HR for HT 2.88, p=0.055, HR for DM 2.01, p=0.045). Presence of either HT or DM (or both) wasindependently associated with lower rate of 5 years survival (HR 8.24, p=0.041). Metformin use was not associated with RFS or OSin whole patient population. However, among patients with diabetes, metformin use was associated with improved 5 years survival(p=0.024) but not with RFS (p=0.47).Conclusion: Our study showed DM and HT to be associated with increased mortality in patients with EC but no link was shownbetween presence of DM/HT and disease recurrence. Metformin might be the treatment of choice in patients with DM and EC, butbeneficial effects are probably through metabolic effects rather than anticancer efficacy.

PDF

___

1. Lino-Silva LS, de León DC, Salcedo-Hernández RA, et al. A high body mass index is not a worse prognostic factor for endometrial carcinoma in a predominantly obese population. Clin Transl Oncol 2013;15:243-7.
2. Barrena Medel NI, Herzog TJ, Deutsch I, et al. Comparison of the prognostic significance of uterine factors and nodal status for endometrial cancer. Am J Obstet Gynecol 2011;204:1-7.
3. Geels YP, Pijnenborg JM, van den Berg-van Erp SH, et al. Absolute depth of myometrial invasion in endometrial cancer is superior to the currently used cut-off value of 50%. Gynecol Oncol 2013;129:285-91.
4. Nicholas Z, Hu N, Ying J, et al. Impact of Comorbid Conditions on Survival in Endometrial Cancer. Am J Clin Oncol 2012;37:131-4.
5. Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci 2013;104:9-14.
6. Chen HF, Liu MD, Chen P, et al. Risks of Breast and Endometrial Cancer in Women with Diabetes: A Population-Based Cohort Study. PLoS One 2013;8:67420.
7. Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 2013;31:2607-18.
8. Friberg E, Orsini N, Mantzoros CS, et al. Diabetes mellitus and risk of endometrial cancer: a metaanalysis. Diabetologia 2007;50:1365-74.
9. Zanders MM, Boll D, van Steenbergen LN, et al. Effect of diabetes on endometrial cancer recurrence and survival. Maturitas 2013;74:37-43.
10. Olson SH, Atoria CL, Cote ML, et al. The impact of race and comorbidity on survival in endometrial cancer. Cancer Epidemiol Biomarkers Prev 2012;21:753-60.
11. Zhang ZH, Su PY, Hao JH, et al. The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies. Int J Gynecol Cancer 2013;23:294- 303.
12. Becker C, Jick SS, Meier CR, et al. Metformin and the risk of endometrial cancer: a case-control analysis. Gynecol Oncol 2013;129:565-9.
13. Cantrell LA, Zhou C, Mendivil A, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategy. Gynecol Oncol 2010;116:92-8.
14. Xie Y, Wang YL, Yu L, et al. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 2011;126:113-20.
15. Zhang Z, Dong L, Sui L, et al. Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. Int J Gynecol Cancer 2011;21:213-21.
16. Nevadunsky NS, Van Arsdale A, Strickler HD, et al. Metformin use and endometrial cancer survival. Gynecol Oncol 2014;132:236-40.
17. Boll D, Verhoeven RH, van der Aa MA, et al. Adherence to national guidelines for treatment and outcome of endometrial cancer stage I in relation to co-morbidity in southern Netherlands 1995-2008. Eur J Cancer 2011;47:1504-10.
18. Folsom AR, Anderson KE, Sweeney C, et al. Diabetes as a risk factor for death following endometrial cancer. Gynecol Oncol 2004;94:740-5.
19. Kauppila A, Grönroos M, Nieminen U. Clinical outcome in endometrial cancer.Obstet Gynecol 1982;60:473- 80.
20. Alektiar KM, Venkatraman E, Abu-Rustum N, et al. Is endometrial carcinoma intrinsically more aggressive in elderly patients? Cancer 2003;98:2368-77.
21. Noto H, Tsujimoto T, Sasazuki T, et al.Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocr Pract 2011;17:616-28.
22. Yuhara H, Steinmaus C, Cohen SE, et al. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol 2011;106:1911- 22.
23. Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 2011;47:1928-37.
24. Wolf I, Sadetzki S, Catane R, et al. Diabetes mellitus and breast cancer. Lancet Oncol 2005;6:103-11.
25. Rosato V, Zucchetto A, Bosetti C, et al. Metabolic syndrome and endometrial cancer risk. Ann Oncol 2011;22:884-9.
26. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010; 60:201-21.
27. Chia VM, Newcomb PA, Trentham-Dietz A, et al. Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis. Int J Gynecol Cancer 2007;17:441-6.
28. Steiner E, Eicher O, Sagemüller J, et al. Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer 2003;13:197-203.
29. Yin M, Zhou J, Gorak EJ, et al. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and metaanalysis. Oncologist 2013;18:1248-55.
30. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854- 865. Erratum in: Lancet 1998;352:1558.